Title |
The association between Lambert–Eaton myasthenic syndrome and small cell lung carcinoma
|
---|---|
Published in |
ImmunoTargets and Therapy, May 2013
|
DOI | 10.2147/itt.s31971 |
Pubmed ID | |
Authors |
Sarah EW Briggs, Paul Gozzard, Denis C Talbot |
Abstract |
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder mediated by autoantibodies to voltage-gated calcium channels. The disorder is diagnosed clinically on the basis of a triad of symptoms (proximal muscle weakness, hyporeflexia, and autonomic disturbance), supported by electrophysiological findings and the presence of autoantibodies. Between 40% and 62% of patients diagnosed with LEMS are found to have small-cell lung cancer (SCLC), almost all of whom develop neurological symptoms before their cancer is diagnosed. Prompt identification of LEMS and appropriate screening for SCLC is key to improving the outcome of both conditions. Here we review the pathophysiology and clinical management of LEMS, focusing particularly on the relationship with SCLC. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 8 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 63% |
Scientists | 3 | 38% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 23 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 3 | 13% |
Researcher | 3 | 13% |
Student > Bachelor | 2 | 9% |
Professor | 2 | 9% |
Lecturer | 1 | 4% |
Other | 2 | 9% |
Unknown | 10 | 43% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 35% |
Social Sciences | 2 | 9% |
Sports and Recreations | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Immunology and Microbiology | 1 | 4% |
Other | 1 | 4% |
Unknown | 9 | 39% |